制药装备

Search documents
东富龙前沿技术闪耀国际舞台 打造行业“智慧制药”的理念
Zhong Zheng Wang· 2025-10-10 13:09
中证报中证网讯(王珞)在近期举行的新加坡ISPE制药会议及展览会(ISPE新加坡展会)上,东富龙 (300171)集中展示了包括生物技术模块化工厂模型、一次性耗材、色谱填料及RTP技术在内的多项前 沿技术与核心解决方案,成为全场焦点。 行业前沿方案国际展会引瞩目 东富龙在国际市场上备受关注的模块化工厂,正悄然改变传统药厂的建设模式。传统药厂建设周期长、 成本高,动辄需2到3年时间,而东富龙的模块化工厂通过"设备+工程"一体化集成,将投产周期压缩至6 个月。 展会期间,东富龙举办的两场Power Talk技术分享会精彩纷呈。东富龙生物技术方案专家Tony Xu分享 了智能生物反应器的一站式解决方案,展示了东富龙如何为生物制药不同阶段提供精准、高效的智能支 持。 凭借硬核的技术实力与系统化的整体解决方案,东富龙吸引了来自新加坡、马来西亚、越南、印尼、澳 大利亚等亚太地区的大量客户驻足深度交流,并引发了与会者的强烈兴趣。 东富龙在新加坡ISPE展会上的成功,是其深化全球化战略的一个缩影。此次参展不仅是东富龙创新成 果的展示,更是其夯实国际市场影响力的关键一步。 东富龙的全球化视野不仅体现在市场拓展上,还体现在其技术 ...
技术破壁与全球协同:东富龙以“中国智造”重塑制药装备产业格局
Zheng Quan Shi Bao Wang· 2025-10-10 11:38
在生物医药产业向高端化、全球化加速迈进的浪潮中,东富龙(300171)正以技术创新为锚点、全球布局 为羽翼,书写着中国制药装备企业从"跟跑"到"领跑"的转型答卷。从国内首条双腔冻干制剂生产线的落 地,到国际化战略合作的深度推进,这家深耕行业三十余载的龙头企业,正以硬核实力诠释"专业技术 服务于生物医药"的使命担当。 技术攻坚:破解行业痛点的"中国方案" 高端生物制剂领域长期存在的活性成分稳定性与使用便捷性失衡难题,终于被中国企业的技术创新破 解。2025年6月,东富龙携手维昇药业、药明生物在成都启动国内首条双腔冻干制剂生产线项目,标志 着我国在该领域实现重大技术突破。这项历经十年研发的核心技术,通过密闭容器内双腔隔离设计,将 冻干药物与稀释剂分别储存,注射前轻按即可完成复溶,不仅省去传统操作的繁琐步骤,更降低了污染 风险与操作误差,为生长激素等长期用药患者带来安全性与依从性的双重提升。 财务数据背后,更显战略定力。2025年上半年,公司营业总收入达24.29亿元,同比增长6.01%,其中国 际业务收入同比大增63.25%至8.05亿元,占营收比重超33%,彰显全球化布局的抗周期韧性。尽管短期 面临盈利承压,但 ...
东富龙控股子公司被判侵犯商业秘密罪 3名高管被判缓刑
Zhong Guo Jing Ying Bao· 2025-10-10 08:27
法院判决,被告赛普过滤犯侵犯商业秘密罪,判处罚金130万元。被告人郑某犯侵犯商业秘密罪,判处 有期徒刑2年9个月,缓刑3年6个月,并处罚金60万元。另外两名个人被告分别被判处2年3个月和1年11 个月,均为缓刑,分别被处罚金35万元和25万元。 对于上述事项,东富龙作为上市公司未信披。 10月10日,《中国经营报》记者联系东富龙方面咨询原因。相关人士表示,赛普过滤是在2024年才成为 东富龙控股子公司,此事发生在控股之前。另外,公告中的郑某为赛普过滤董事长法定代表人。 赛普过滤成立于2021年3月。目前,赛普过滤为东富龙持股52%的控股子公司。历史信息显示,2024年 10月17日,东富龙对赛普过滤持股比例由此前的25.6%上升至52%,取得控制权并将其纳入财务合并范 围。 2025年上半年,赛普过滤营业收入为892.64万元,净利润为-1777.52万元。而上年同期,营业收入和净 利润均为0。 今年9月15日,杭州市萧山区人民法院对(2024)浙0109刑初247号案件作出一审判决。 本案前后历时2年6个月,案情较为复杂,涉案商业秘密内容为超滤膜包后道组装工序中使用的单元层和 外围封装模具所涉技术信息。 1 ...
汉邦科技9月30日获融资买入1215.93万元,融资余额8002.81万元
Xin Lang Cai Jing· 2025-10-09 01:42
Core Viewpoint - Hanbang Technology's stock performance and financial metrics indicate a mixed outlook, with a slight decline in net profit despite revenue growth, and significant financing activity suggesting investor interest [1][2]. Financing Activity - On September 30, Hanbang Technology experienced a financing buy-in of 12.16 million yuan, with a net financing buy of 10.40 million yuan after repayments [1]. - The total financing balance as of September 30 is 80.03 million yuan, accounting for 10.60% of the company's market capitalization [1]. Shareholder and Financial Performance - As of June 30, the number of shareholders decreased by 48.43% to 9,372, while the average circulating shares per person increased by 93.92% to 1,764 shares [2]. - For the first half of 2025, Hanbang Technology reported a revenue of 349 million yuan, reflecting a year-on-year growth of 5.99%, but the net profit attributable to shareholders decreased by 26.24% to 27.80 million yuan [2]. Business Overview - Hanbang Technology, established on October 28, 1998, specializes in providing separation and purification equipment, consumables, and technical solutions for the pharmaceutical and life sciences sectors [1]. - The revenue composition includes 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1]. Institutional Holdings - As of June 30, 2025, the largest circulating shareholder is Dongfanghong Medical Upgrade Stock Initiation A, holding 483,700 shares as a new shareholder [2].
迦南科技控股股东1个月减持1493.3万股 套现7379.5万
Zhong Guo Jing Ji Wang· 2025-09-26 08:05
2025年9月18日,迦南科技披露了《关于控股股东减持公司股份触及1%整数倍的公告》,迦南集团于 2025年9月16日通过大宗交易方式减持迦南科技股份410.00万股,占迦南科技总股本的0.8237%,其持股 比例从13.7137%下降至12.8900%,本次权益变动触及1%的整数倍。 经计算,迦南集团于2025年8月25至2025年9月24日期间合计减持迦南科技1,493.25万股,减持金额约为 7,379.51万元。 迦南科技于2025年7月18日披露了《关于控股股东暨部分董事减持股份的预披露公告》,其中迦南集团 持有迦南科技股份7,569.32万股(占迦南科技总股本15.21%),计划自公告披露之日起15个交易日后的3个 月内(即2025年8月11日至2025年11月10日)以集中竞价或大宗交易方式减持迦南科技股份合计不超过 1,493.2699万股(占迦南科技总股本3.00%);黄斌斌持有迦南科技股份673.20万股(占迦南科技总股本 1.35%),计划自公告披露之日起15个交易日后的3个月内(即2025年8月11日至2025年11月10日)以集中竞 价或大宗交易方式减持迦南科技股份合计不超过168. ...
汉邦科技9月22日获融资买入410.11万元,融资余额9268.22万元
Xin Lang Cai Jing· 2025-09-23 01:45
Core Insights - Hanbang Technology's stock decreased by 0.83% on September 22, with a trading volume of 22.01 million yuan [1] - The company reported a net financing purchase of 1.136 million yuan on the same day, with a total financing balance of 92.68 million yuan, accounting for 12.27% of its market capitalization [1] Financing Overview - On September 22, Hanbang Technology had a financing buy amount of 4.101 million yuan and a financing repayment of 2.965 million yuan [1] - The company had no short selling activity on the same day, with a short selling balance of 0 yuan [1] Company Profile - Hanbang Technology, established on October 28, 1998, is located in Huai'an Economic and Technological Development Zone, Jiangsu Province [1] - The company specializes in providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] - The revenue composition includes 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1] Financial Performance - As of June 30, 2025, Hanbang Technology reported a revenue of 349 million yuan, a year-on-year increase of 5.99%, while the net profit attributable to shareholders decreased by 26.24% to 27.7976 million yuan [2] - The number of shareholders decreased by 48.43% to 9,372, while the average circulating shares per person increased by 93.92% to 1,764 shares [2] Shareholder Information - As of June 30, 2025, the largest circulating shareholder is Dongfanghong Medical Upgrade Stock Initiation A (015052), holding 483,700 shares as a new shareholder [2]
东富龙:提升产品智能化,赋能制药装备新发展
Quan Jing Wang· 2025-09-19 12:09
Group 1 - The core viewpoint of the article highlights the increasing trend towards automation and intelligence in pharmaceutical equipment, driven by technological advancements [1] - The company provides various information systems software such as MES, WMS, QMS, and SCADA, offering comprehensive smart manufacturing solutions to clients [1] - Dongfulong is identified as a comprehensive pharmaceutical equipment service provider, delivering process, core equipment, and system engineering solutions to global pharmaceutical enterprises [1]
调研速递|东富龙接受广大投资者调研,聚焦股价、业务布局等要点
Xin Lang Zheng Quan· 2025-09-19 11:48
Core Viewpoint - Dongfulong Technology Group held an online earnings briefing to address investor concerns regarding stock performance, business layout, and product feedback, emphasizing strategic planning and overseas marketing efforts to enhance competitiveness and brand recognition [1][2]. Business Layout - The company is enhancing its market share in the pharmaceutical equipment sector through both organic growth and mergers and acquisitions, considering innovative models such as equipment equity participation or leasing [2]. - Dongfulong's main business segments include bioprocessing, formulation equipment, engineering solutions, and food equipment engineering, with new business expansions in the healthcare sector contributing to revenue, although specific growth data for the first half of the year was not disclosed [2]. Product Feedback - As a leading domestic pharmaceutical equipment provider, Dongfulong's products are noted for their high technical content and intelligence, performing well across various customer applications [2]. - The company offers integrated solutions including MES, WMS, QMS, and SCADA systems, reflecting a trend towards automation and intelligence in pharmaceutical equipment [2].
东富龙(300171) - 300171东富龙2025年上海辖区上市公司集体接待日暨中报业绩说明会20250919
2025-09-19 11:08
Group 1: Company Strategy and Market Position - The company aims to enhance investor confidence by actively expanding its product chain and strengthening its overseas marketing network to increase market share [2][3] - The company is a leading player in the domestic pharmaceutical equipment sector, with high technical content and automation levels in its products [3][4] - The company is considering innovative models such as equipment equity participation or leasing to boost market share [3] Group 2: Financial Performance and Shareholder Value - The company is focused on developing new products to meet customer demands and is actively securing domestic and international orders to improve operational performance [3] - The company reported significant growth in orders within the biopharmaceutical and vaccine production sectors, which are key strategic areas [3] - The company’s revenue contribution from new business expansions in the healthcare sector is detailed in its semi-annual report [3] Group 3: Technological Advancements - The company is enhancing its product intelligence through automation and smart manufacturing solutions, which improve production efficiency and product quality [4] - The company provides various information systems software to offer comprehensive smart manufacturing solutions to clients [4] Group 4: Investment and Partnerships - The company holds a 20% stake in Yantai Saibo Biotechnology Co., which is a minority investment and does not involve operational management [3] - The company’s subsidiary, Shanghai Bohao, is primarily focused on chip detection and single-cell sequencing, with no current plans to enter the brain-computer interface chip sector [3][4]
楚天科技(300358) - 楚天科技投资者关系管理信息20250919
2025-09-19 09:26
楚天科技股份有限公司 投资者关系活动记录表 编号:2025-009 | | □特定对象调研 □分析师会议 | | --- | --- | | 媒体采访 调研活动类别 | 业绩说明会 | | | □新闻发布会 □路演活动 | | 现场参观 | □其他 | | 参与单位名称 | 投资者网上提问 | | 及人员姓名 | | | 时 间 2025 | 年 9 月 19 日 14:30-17:00 | | 地 | 公司通过全景网"投资者关系互动平台"(https://ir.p5w.net) | | 点 | 采用网络远程的方式召开业绩说明会 | | 上市公司接待 | 董事会秘书:黄玉婷 | | 人员姓名 | 证券事务代表:周德伟 | | 问题 | 1、你好!请问公司年度扭亏为盈的目标能不能完成? | | | 您好!公司在《2024 年年度报告》中披露了 2025 年的经营目标为 | | | 实现年度扭亏为盈,截至 2025 年上半年,公司综合毛利率持续提升, | | | 严控各项费用及成本。2025 年上半年亏损同比大幅收窄,公司将持 | | | 续进行管理优化、巩固国内市场、加大国际市场开拓、加强产品开 | | ...